Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 118 filers reported holding Y-MABS THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $25,642,000 | -46.8% | 1,581,845 | -6.3% | 0.03% | -49.2% |
| Q3 2021 | $48,191,000 | +8.2% | 1,688,556 | +28.1% | 0.06% | +11.3% |
| Q2 2021 | $44,558,000 | +11.8% | 1,318,279 | +0.0% | 0.05% | +6.0% |
| Q1 2021 | $39,853,000 | -23.1% | 1,317,900 | +25.8% | 0.05% | -20.6% |
| Q4 2020 | $51,858,000 | +86.2% | 1,047,416 | +44.3% | 0.06% | +61.5% |
| Q3 2020 | $27,857,000 | +3.0% | 725,628 | +15.9% | 0.04% | -9.3% |
| Q2 2020 | $27,055,000 | +89.6% | 626,266 | +14.6% | 0.04% | +38.7% |
| Q1 2020 | $14,267,000 | – | 546,640 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 191,176 | $2,271,000 | 2.63% |
| Sofinnova Investments, Inc. | 2,194,278 | $26,068,000 | 1.98% |
| MPM BioImpact LLC | 443,702 | $5,271,000 | 1.42% |
| Soleus Capital Management, L.P. | 238,982 | $2,839,000 | 0.37% |
| Lombard Odier Asset Management (Switzerland) SA | 221,774 | $2,635,000 | 0.21% |
| Artal Group S.A. | 400,000 | $4,752,000 | 0.20% |
| Polar Capital Holdings Plc | 2,877,671 | $34,187,000 | 0.15% |
| ASHFORD CAPITAL MANAGEMENT INC | 106,770 | $1,268,000 | 0.14% |
| Cormorant Asset Management, LP | 150,000 | $1,782,000 | 0.14% |
| Virtus ETF Advisers LLC | 23,646 | $281,000 | 0.13% |